Home  |  Contact

UniProtKB/Swiss-Prot Q7Z4L5: Variant p.Asp755Tyr

Tetratricopeptide repeat protein 21B
Gene: TTC21B
Variant information

Variant position:  755
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Type of variant:  LP/P [Disclaimer]
The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance

Residue change:  From Aspartate (D) to Tyrosine (Y) at position 755 (D755Y, p.Asp755Tyr).
Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.

Physico-chemical properties:  Change from medium size and acidic (D) to large size and aromatic (Y)
The physico-chemical property of the reference and variant residues and the change implicated.

BLOSUM score:  -3
The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page

Variant description:  In SRTD4; functionally null mutation in vitro.
Any additional useful information about the variant.



Sequence information

Variant position:  755
The position of the amino-acid change on the UniProtKB canonical protein sequence.

Protein sequence length:  1316
The length of the canonical sequence.

Location on the sequence:   ILEPEEAIVAYEQALNQNPK  D GTLASKMGKALIKTHNYSMA
The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.

Residue conservation: 
The multiple alignment of the region surrounding the variant against various orthologous sequences.

Human                         ILEPEEAIVAYEQALNQNPKDGTLASKMGKALIKTHNYSMA

Mouse                         IQEPEEAIVAYEQALNQNPKDGTLARKIGKALVKTHNYSKA

Xenopus laevis                IQEPEKALEVYNEALHKNPQDASLANRIGQALIKTHQYKKA

Sequence annotation in neighborhood:  
The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.

TypePositionsDescription
Chain 1 – 1316 Tetratricopeptide repeat protein 21B
Repeat 722 – 755 TPR 9
Alternative sequence 483 – 1316 Missing. In isoform 2.


Literature citations

TTC21B contributes both causal and modifying alleles across the ciliopathy spectrum.
Davis E.E.; Zhang Q.; Liu Q.; Diplas B.H.; Davey L.M.; Hartley J.; Stoetzel C.; Szymanska K.; Ramaswami G.; Logan C.V.; Muzny D.M.; Young A.C.; Wheeler D.A.; Cruz P.; Morgan M.; Lewis L.R.; Cherukuri P.; Maskeri B.; Hansen N.F.; Mullikin J.C.; Blakesley R.W.; Bouffard G.G.; Gyapay G.; Rieger S.; Tonshoff B.; Kern I.; Soliman N.A.; Neuhaus T.J.; Swoboda K.J.; Kayserili H.; Gallagher T.E.; Lewis R.A.; Bergmann C.; Otto E.A.; Saunier S.; Scambler P.J.; Beales P.L.; Gleeson J.G.; Maher E.R.; Attie-Bitach T.; Dollfus H.; Johnson C.A.; Green E.D.; Gibbs R.A.; Hildebrandt F.; Pierce E.A.; Katsanis N.;
Nat. Genet. 43:189-196(2011)
Cited for: INVOLVEMENT IN CILIOPATHIES; VARIANTS NPHP12 ARG-150; LEU-209; SER-231; ARG-566 AND CYS-1167; VARIANTS SRTD4 SER-231; TYR-755 AND PRO-795; VARIANTS JBTS11 ASN-591; CYS-867 AND VAL-1186; VARIANTS TYR-60; ARG-66; GLU-157; LEU-222; SER-231; ASN-242; CYS-255; VAL-280; SER-327; CYS-347; GLY-411; ARG-412; GLU-424; CYS-616; VAL-624; ARG-645; THR-724; LEU-753; VAL-844; HIS-867; ARG-869; GLN-939; TRP-939; VAL-1002; VAL-1011; CYS-1035; ASN-1041; ARG-1103; SER-1208; HIS-1284 AND GLY-1311; CHARACTERIZATION OF VARIANTS NPHP12 ARG-150; LEU-209; SER-231; ARG-566 AND CYS-1167; CHARACTERIZATION OF VARIANTS SRTD4 SER-231; TYR-755 AND PRO-795; CHARACTERIZATION OF VARIANTS JBTS11 ASN-591; CYS-867 AND VAL-1186; CHARACTERIZATION OF VARIANTS TYR-60; GLU-157; LEU-222; SER-231; CYS-255; VAL-280; SER-327; CYS-347; GLY-411; LEU-753; VAL-844; HIS-867; ARG-869; GLN-939; TRP-939; VAL-1002; ARG-1103; ASN-1041 AND SER-1208;

Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.